---
schema_version: "secwatch.filing_event.v1"
accession: "0001157523-23-001312"
form_type: "8-K"
ticker: "EWTX"
cik: "0001710072"
company_name: "Edgewise Therapeutics, Inc."
filed_at: "2023-08-10T23:59:59+00:00"
generated_at: "2026-06-11T18:21:32.279444+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Edgewise reports Q2 2023 net loss $21.5M; positive ARCH 12-month data for EDG-5506

## Summary
- Cash, equivalents and marketable securities $310M as of June 30, 2023.
- R&D expenses $19.6M, G&A $5.8M; net loss $0.34 per share.
- ARCH study: CK reduced 37% (p=0.001), fast skeletal troponin I reduced 79% (p<0.0001) at 12 months.
- GRAND CANYON pivotal cohort for Becker expected to start enrollment in 2H 2023; ~120 patients.
- Phase 1 trial of EDG-7500 for HCM expected to start in 2H 2023, subject to IND clearance.

## SEC filing metadata
- accession: 0001157523-23-001312
- form_type: 8-K
- ticker: EWTX
- cik: 0001710072
- company_name: Edgewise Therapeutics, Inc.
- filed_at: 2023-08-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1710072/000115752323001312/0001157523-23-001312-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1710072/000115752323001312/a53523949.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001157523-23-001312
- JSON: https://secwatch.observer/filing/0001157523-23-001312.json
- Plain text: https://secwatch.observer/filing/0001157523-23-001312.txt

## Key facts
- Earnings Releases
  Edgewise Therapeutics, Inc. reported financial results for second quarter of 2023.
  - Period: second quarter of 2023
  - Result: reported results
  source text: Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative treatments for severe, genetic neuromuscular and cardiac disorders for which there is significant unmet medical need, today reported financial results for the second quarter of 2023 and recent business highlights.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1710072/000115752323001312/0001157523-23-001312-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.